5-bromo-4-phenylpyridin-2-amine | 1029128-27-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-bromo-4-phenylpyridin-2-amine
• CAS: 1029128-27-5
• 化学式: C₁₁H₉BrN₂
• 分子量: 249.11
• InChiKey: GFKPXWUYMOUSMN-UHFFFAOYSA-N

物化性质

• 沸点：
  346.5±42.0 °C(Predicted)
• 密度：
  1.496±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-bromo-4-phenylpyridin-2-amine 、 sodium methylate 在 铜 、 氯化铵 作用下， 以 甲醇 、 水 、 乙酸乙酯 为溶剂， 反应 3.0h， 以44%的产率得到5-methoxy-4-phenylpyridin-2-amine
  参考文献：
  名称：

  WO2008/63625

  摘要：

  公开号：

文献信息

• Pharmaceutically active compounds
  申请人：BERGENBIO ASA

  公开号：US10336702B2

  公开（公告）日：2019-07-02

  The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.

  本发明涉及通式（I）化合物和含有此类化合物的药物组合物。这些化合物和组合物具有宝贵的药物特性。特别是，它们可用于治疗癌症。本发明还公开了新型中间体和新型制备方法。
• [EN] INHIBITORS OF AKT KINASE<br/>[FR] COMPOSÉS PHARMACEUTIQUEMENT ACTIFS
  申请人：BERGENBIO AS

  公开号：WO2016102672A3

  公开（公告）日：2016-08-18
• INHIBITORS OF AKT KINASE
  申请人：BerGenBio ASA

  公开号：EP3240784A2

  公开（公告）日：2017-11-08
• PHARMACEUTICALLY ACTIVE COMPOUNDS
  申请人：BERGENBIO AS

  公开号：US20180029985A1

  公开（公告）日：2018-02-01

  The invention is directed to compounds of general formula (I), and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.
• Pharmaceutically Active Compounds
  申请人：BerGenBio ASA

  公开号：US20210070708A1

  公开（公告）日：2021-03-11

  The invention is directed to compounds of general formula (I) and pharmaceutical compositions containing such compounds. The compounds and compositions have valuable pharmaceutical properties. In particular, they may be used for the treatment of cancer. Novel intermediates and novel methods of preparation are also disclosed.